Sultopride: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
Turky Alkathery (talk | contribs)
CMEUser, nocaptcha, Administrators
6,562 edits
Created page with "{{Drugbox | Verifiedfields = changed | verifiedrevid = 470474772 | IUPAC_name = ''N''-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxy-benzamide | image = Sultopride..."
 
WikiBot (talk | contribs)
Bots, Bureaucrats, bureaucrats, interwiki, nocaptcha, Administrators
57,550 edits
m Protected "Sultopride": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite))
 
(2 intermediate revisions by one other user not shown)
Line 3: Line 3:
| verifiedrevid = 470474772
| verifiedrevid = 470474772
| IUPAC_name = ''N''-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxy-benzamide
| IUPAC_name = ''N''-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxy-benzamide
| image = Sultopride structure.svg
| image = Sultopride.png


<!--Clinical data-->
<!--Clinical data-->
Line 44: Line 44:
| StdInChIKey = UNRHXEPDKXPRTM-UHFFFAOYSA-N
| StdInChIKey = UNRHXEPDKXPRTM-UHFFFAOYSA-N
}}
}}
 
              __NOTOC__
{{SI}}
{{CMG}}
==Overview==
 
'''Sultopride''' ('''Barnetil''', '''Barnotil''', '''Topral''') is an [[atypical antipsychotic]] of the [[benzamide]] [[chemical class]] used in [[Europe]], [[Japan]], and [[Hong Kong]] for the treatment of [[schizophrenia]].<ref name="isbn3-527-31058-4">{{cite book | author = José Miguel Vela; Helmut Buschmann; Jörg Holenz; Antonio Párraga; Antoni Torrens | title = Antidepressants, Antipsychotics, Anxiolytics: From Chemistry and Pharmacology to Clinical Application | publisher = Wiley-VCH | location = Weinheim | year = 2007 | isbn = 3-527-31058-4 | url = http://books.google.com/books?id=yXD4QA-Y_Z0C&lpg=PA537}}</ref><ref name="isbn3-88763-075-0">{{cite book | author = Swiss Pharmaceutical Society | title = Index Nominum 2000: International Drug Directory (Book with CD-ROM) | publisher = Medpharm Scientific Publishers | location = Boca Raton | year = 2000| isbn = 3-88763-075-0 | url = http://books.google.com/?id=5GpcTQD_L2oC&lpg=PA1624&dq=sultopride&pg=PA983}}</ref><ref name="isbn3-7692-2114-1">{{cite book| title = European Drug Index, 4th Edition | publisher = CRC Press | location = Boca Raton | year = 1998 | isbn = 3-7692-2114-1| url = http://books.google.com/books?id=HiSdvzs2pPAC&lpg=PA136}}</ref> It was launched by [[Sanofi-Aventis]] in 1976.<ref name="isbn3-527-31058-4" /> Sultopride acts as a [[binding selectivity|selective]] [[D2 receptor|D<sub>2</sub>]] and [[D3 receptor|D<sub>3</sub> receptor]] [[receptor antagonist|antagonist]].<ref name="pmid16135699">{{cite journal  | title = Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 315 | issue = 3 | pages = 1278–87 | year = 2005| pmid = 16135699 | doi = 10.1124/jpet.105.092155  | last1 = Burstein  | first1 = E. S.  | last2 = Ma  | first2 = J  | last3 = Wong  | first3 = S  | last4 = Gao  | first4 = Y  | last5 = Pham  | first5 = E  | last6 = Knapp  | first6 = AE  | last7 = Nash  | first7 = NR  | last8 = Olsson  | first8 = R  | last9 = Davis  | first9 = RE  }}</ref> It has also been shown to have clinically relevant [[affinity (pharmacology)|affinity]] for the [[GHB receptor]] as well, a property it shares in common with [[amisulpride]] and [[sulpiride]].<ref>{{cite journal |author=Maitre M, Ratomponirina C, Gobaille S, Hodé Y, Hechler V |title=Displacement of [3H] gamma-hydroxybutyrate binding by benzamide neuroleptics and prochlorperazine but not by other antipsychotics |journal=Eur J Pharmacol. |volume=256 |issue=2 |pages=211–4 |year=1994 |pmid=7914168 |doi=10.1016/0014-2999(94)90248-8 }}</ref>
'''Sultopride''' ('''Barnetil''', '''Barnotil''', '''Topral''') is an [[atypical antipsychotic]] of the [[benzamide]] [[chemical class]] used in [[Europe]], [[Japan]], and [[Hong Kong]] for the treatment of [[schizophrenia]].<ref name="isbn3-527-31058-4">{{cite book | author = José Miguel Vela; Helmut Buschmann; Jörg Holenz; Antonio Párraga; Antoni Torrens | title = Antidepressants, Antipsychotics, Anxiolytics: From Chemistry and Pharmacology to Clinical Application | publisher = Wiley-VCH | location = Weinheim | year = 2007 | isbn = 3-527-31058-4 | url = http://books.google.com/books?id=yXD4QA-Y_Z0C&lpg=PA537}}</ref><ref name="isbn3-88763-075-0">{{cite book | author = Swiss Pharmaceutical Society | title = Index Nominum 2000: International Drug Directory (Book with CD-ROM) | publisher = Medpharm Scientific Publishers | location = Boca Raton | year = 2000| isbn = 3-88763-075-0 | url = http://books.google.com/?id=5GpcTQD_L2oC&lpg=PA1624&dq=sultopride&pg=PA983}}</ref><ref name="isbn3-7692-2114-1">{{cite book| title = European Drug Index, 4th Edition | publisher = CRC Press | location = Boca Raton | year = 1998 | isbn = 3-7692-2114-1| url = http://books.google.com/books?id=HiSdvzs2pPAC&lpg=PA136}}</ref> It was launched by [[Sanofi-Aventis]] in 1976.<ref name="isbn3-527-31058-4" /> Sultopride acts as a [[binding selectivity|selective]] [[D2 receptor|D<sub>2</sub>]] and [[D3 receptor|D<sub>3</sub> receptor]] [[receptor antagonist|antagonist]].<ref name="pmid16135699">{{cite journal  | title = Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 315 | issue = 3 | pages = 1278–87 | year = 2005| pmid = 16135699 | doi = 10.1124/jpet.105.092155  | last1 = Burstein  | first1 = E. S.  | last2 = Ma  | first2 = J  | last3 = Wong  | first3 = S  | last4 = Gao  | first4 = Y  | last5 = Pham  | first5 = E  | last6 = Knapp  | first6 = AE  | last7 = Nash  | first7 = NR  | last8 = Olsson  | first8 = R  | last9 = Davis  | first9 = RE  }}</ref> It has also been shown to have clinically relevant [[affinity (pharmacology)|affinity]] for the [[GHB receptor]] as well, a property it shares in common with [[amisulpride]] and [[sulpiride]].<ref>{{cite journal |author=Maitre M, Ratomponirina C, Gobaille S, Hodé Y, Hechler V |title=Displacement of [3H] gamma-hydroxybutyrate binding by benzamide neuroleptics and prochlorperazine but not by other antipsychotics |journal=Eur J Pharmacol. |volume=256 |issue=2 |pages=211–4 |year=1994 |pmid=7914168 |doi=10.1016/0014-2999(94)90248-8 }}</ref>


==References==
==References==
{{Reflist}}
{{Reflist|2}}




{{Antipsychotics}}
{{Antipsychotics}}
{{Dopaminergics}}
{{GHBergics}}


[[Category:Benzamides]]
 
 
[[Category:Pyrrolidines]]
[[Category:Pyrrolidines]]
[[Category:Phenol ethers]]
[[Category:Phenol ethers]]
[[Category:Sulfones]]
[[Category:Sulfones]]
[[Category:GHB receptor ligands]]
[[Category:Drug]]
 
 
{{nervous-system-drug-stub}}

Latest revision as of 17:11, 20 August 2015

Sultopride
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration		Oral, IM
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Elimination half-life3–5 hours
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC17H26N2O4S
Molar mass354.46 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Sultopride

Articles

Most recent articles on Sultopride

Most cited articles on Sultopride

Review articles on Sultopride

Articles on Sultopride in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Sultopride

Images of Sultopride

Photos of Sultopride

Podcasts & MP3s on Sultopride

Videos on Sultopride

Evidence Based Medicine

Cochrane Collaboration on Sultopride

Bandolier on Sultopride

TRIP on Sultopride

Clinical Trials

Ongoing Trials on Sultopride at Clinical Trials.gov

Trial results on Sultopride

Clinical Trials on Sultopride at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Sultopride

NICE Guidance on Sultopride

NHS PRODIGY Guidance

FDA on Sultopride

CDC on Sultopride

Books

Books on Sultopride

News

Sultopride in the news

Be alerted to news on Sultopride

News trends on Sultopride

Commentary

Blogs on Sultopride

Definitions

Definitions of Sultopride

Patient Resources / Community

Patient resources on Sultopride

Discussion groups on Sultopride

Patient Handouts on Sultopride

Directions to Hospitals Treating Sultopride

Risk calculators and risk factors for Sultopride

Healthcare Provider Resources

Symptoms of Sultopride

Causes & Risk Factors for Sultopride

Diagnostic studies for Sultopride

Treatment of Sultopride

Continuing Medical Education (CME)

CME Programs on Sultopride

International

Sultopride en Espanol

Sultopride en Francais

Business

Sultopride in the Marketplace

Patents on Sultopride

Experimental / Informatics

List of terms related to Sultopride

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Sultopride (Barnetil, Barnotil, Topral) is an atypical antipsychotic of the benzamide chemical class used in Europe, Japan, and Hong Kong for the treatment of schizophrenia.[1][2][3] It was launched by Sanofi-Aventis in 1976.[1] Sultopride acts as a selective D2 and D3 receptor antagonist.[4] It has also been shown to have clinically relevant affinity for the GHB receptor as well, a property it shares in common with amisulpride and sulpiride.[5]

References

  1. ↑ 1.0 1.1 José Miguel Vela; Helmut Buschmann; Jörg Holenz; Antonio Párraga; Antoni Torrens (2007). Antidepressants, Antipsychotics, Anxiolytics: From Chemistry and Pharmacology to Clinical Application. Weinheim: Wiley-VCH. ISBN 3-527-31058-4.
  2. ↑ Swiss Pharmaceutical Society (2000). Index Nominum 2000: International Drug Directory (Book with CD-ROM). Boca Raton: Medpharm Scientific Publishers. ISBN 3-88763-075-0.
  3. ↑ European Drug Index, 4th Edition. Boca Raton: CRC Press. 1998. ISBN 3-7692-2114-1.
  4. ↑ Burstein, E. S.; Ma, J; Wong, S; Gao, Y; Pham, E; Knapp, AE; Nash, NR; Olsson, R; Davis, RE (2005). "Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist". The Journal of Pharmacology and Experimental Therapeutics. 315 (3): 1278–87. doi:10.1124/jpet.105.092155. PMID 16135699.
  5. ↑ Maitre M, Ratomponirina C, Gobaille S, Hodé Y, Hechler V (1994). "Displacement of [3H] gamma-hydroxybutyrate binding by benzamide neuroleptics and prochlorperazine but not by other antipsychotics". Eur J Pharmacol. 256 (2): 211–4. doi:10.1016/0014-2999(94)90248-8. PMID 7914168.


Retrieved from "https://www.wikidoc.org/index.php?title=Sultopride&oldid=1137592"